An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg levonogestrel/30 μg ethinylestradiol in Thai women

Contraception

Volumn 69, Issue 1, 2004, Pages 23-26

  Suthipongse, Wichit ^a   Taneepanichskul, Surasak ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Drospirenone; Ethinylestradiol; Levonorgestrel; Oral contraceptives

Indexed keywords

DROSPIRENONE; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AMENORRHEA; ARTICLE; BODY WEIGHT; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MEAN ARTERIAL PRESSURE; MENSTRUAL CYCLE; NAUSEA; NORMAL HUMAN; PREGNANCY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SPOTTING; STATISTICAL SIGNIFICANCE;

EID: 0346023972     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.08.014     Document Type: Article

References (14)

1. Lara-Torre E., Schroeder B. Adolescent compliance and side effects with Quick Start initiation of oral contraceptive pills. Contraception. 66:2002;81-85.
2. Parsey K.S., Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 61:2000;105-111.
3. Fuhrmann U., Krattenmacher R., Slater E.P., Fritzemeier K.H. The novel progestin drospirenone and its natural counterpart progesterone biochemical profile and antiandrogenic potential . Contraception. 54:1996;243-251.
4. Krattenmacher R. Drospirenone pharmacokinetics of a unique progestogen . Contraception. 62:2000;29-38.
5. Ludicke F., Johannisson E., Helmerhorst F.M., Campana A., Foidart J., Heithecker R. Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 76:2001;102-107.
6. Mansour D. Yasmin - a new oral contraceptive, a new progestogen the reasons why . Eur J Contracept Reprod Health Care. 5:2000;9-16.
7. Oelkers W., Foridart J.M., Dombrovicz N., Welter A., Heithecker R. Effect of a new oral contraceptive containing an antimineralocorticoid progestrogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 80:1995;1816-1821.
8. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 5:2000;124-134.
9. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. 1996;World Health Organization, Geneva.
10. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care. 5:2000;17-24.
11. Oelkers W., Helmerhorst F.M., Wuttke W., Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol. 14:2000;204-213.
12. Muhn P., Krattenmacher R., Beier S., Elger W., Schillinger E. Drospirenone a novel progestogen with antimineralocoticoid and antiandrogenic activity. Pharmacological characterization in animal models . Contraception. 51:1995;99-110.
13. Loudon N.B., Kirkman R.J.E., Dewsbury J.A. A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30. Eur J Obstet Gynecol Reprod Biol. 34:1990;257-266.
14. Endrikat J., Hite R., Bannemerschul R., Gerlinger R.C., Schmidt W. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 μg ethinylestradiol/100 μg levonorgestrel and 20 μg ethinylestradiol/500 μg norethisterone. Contraception. 64:2001;3-10.